Tudor Investment Corp ET AL trimmed its position in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 80.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,023 shares of the biopharmaceutical company’s stock after selling 55,038 shares during the quarter. Tudor Investment Corp ET AL’s holdings in Bellicum Pharmaceuticals were worth $152,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Ronald Blue & Co. LLC acquired a new stake in shares of Bellicum Pharmaceuticals during the second quarter valued at about $117,000. Clear Harbor Asset Management LLC acquired a new stake in shares of Bellicum Pharmaceuticals during the second quarter valued at about $118,000. Voya Investment Management LLC acquired a new stake in shares of Bellicum Pharmaceuticals during the second quarter valued at about $132,000. American International Group Inc. boosted its stake in shares of Bellicum Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 852 shares in the last quarter. Finally, Marshall Wace North America L.P. acquired a new stake in shares of Bellicum Pharmaceuticals during the first quarter valued at about $177,000. 55.74% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Bellicum Pharmaceuticals, Inc. (BLCM) opened at 10.41 on Thursday. The firm’s market capitalization is $345.88 million. The stock’s 50 day moving average price is $11.04 and its 200-day moving average price is $11.42. Bellicum Pharmaceuticals, Inc. has a 52 week low of $7.41 and a 52 week high of $23.11.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same period in the previous year, the firm earned ($0.61) earnings per share. Equities analysts predict that Bellicum Pharmaceuticals, Inc. will post ($3.02) earnings per share for the current year.

A number of brokerages have recently commented on BLCM. ValuEngine raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, September 18th. Jefferies Group LLC reissued a “buy” rating and set a $16.00 price target on shares of Bellicum Pharmaceuticals in a research note on Thursday, September 14th. BidaskClub raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Raymond James Financial, Inc. set a $18.00 price target on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. Bellicum Pharmaceuticals has a consensus rating of “Hold” and an average price target of $26.20.

TRADEMARK VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/19/tudor-investment-corp-et-al-sells-55038-shares-of-bellicum-pharmaceuticals-inc-blcm.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM).

Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Stock Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.